On April 23, AstraZeneca
- Net sales increased by 12.7%, driven by sales of Nexium, Seroquel, and Crestor.
- The company expects to launch Symbicort, one of its key products, in the U.S. in fiscal 2007.
- On April 23, the company announced that it is to acquire MedImmune
(NASDAQ:MEDI) for $58 per share with a total enterprise value of $15.2 billion. One Fool doesn't think too much of this deal.
(Figures in millions, except per-share data.)
Income Statement HighlightsQ1 2007 | Q1 2006 | Change | |
|---|---|---|---|
Sales | $6,966 | $6,180 | 12.7% |
Net Profit | $1,564 | $1,424 | 9.8% |
EPS | $1.02 | $0.90 | 13.3% |
Diluted Shares | 1,531 | 1,582 | (3.2%) |
Get back to basics with the income statement.
Margin Checkup
Q1 2007 | Q1 2006 | Change* | |
|---|---|---|---|
Gross Margin | 78.7% | 79.8% | (1.1) |
Operating Margin | 31.2% | 32.0% | (0.8) |
Net Margin | 22.5% | 23.0% | (0.6) |
Margins are the earnings engine.
Balance Sheet Highlights
Assets | Q1 2007 | Q1 2006 | Change |
|---|---|---|---|
Cash + ST Invest. | $6,416 | $6,065 | 5.8% |
Accounts Rec. | $6,238 | $5,158 | 20.9% |
Inventory | $2,294 | $2,180 | 5.2% |
Liabilities | Q1 2007 | Q1 2006 | Change |
|---|---|---|---|
Accounts Payable | $7,012 | $5,499 | 27.5% |
Long-Term Debt | $1,087 | $1,078 | 0.8% |
The balance sheet reflects the company's health.
Cash Flow Highlights
Q1 2007 | Q1 2006 | Change | |
|---|---|---|---|
Cash From Ops. | $2,187 | $1,512 | 44.6% |
Capital Expenditures | $365 | $384 | (4.9%) |
Free Cash Flow | $1,822 | $1,128 | 61.5% |
Free cash flow is a Fool's best friend.
Related Foolishness:
- A Fresh Outlook at AstraZeneca
- GlaxoSmithKline Gets Ready for the Vaccine Wars
- Genentech Is Still Healthy
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
